Inflammation and its resolution as determinants of acute coronary syndromes - PubMed (original) (raw)
Review
Inflammation and its resolution as determinants of acute coronary syndromes
Peter Libby et al. Circ Res. 2014.
Abstract
Inflammation contributes to many of the characteristics of plaques implicated in the pathogenesis of acute coronary syndromes. Moreover, inflammatory pathways not only regulate the properties of plaques that precipitate acute coronary syndromes but also modulate the clinical consequences of the thrombotic complications of atherosclerosis. This synthesis will provide an update on the fundamental mechanisms of inflammatory responses that govern acute coronary syndromes and also highlight the ongoing balance between proinflammatory mechanisms and endogenous pathways that can promote the resolution of inflammation. An appreciation of the countervailing mechanisms that modulate inflammation in relation to acute coronary syndromes enriches our fundamental understanding of the pathophysiology of this important manifestation of atherosclerosis. In addition, these insights provide glimpses into potential novel therapeutic interventions to forestall this ultimate complication of the disease.
Keywords: apoptosis; inflammation; inflammation resolution; macrophage; myocardial infarction; plaque necrosis.
© 2014 American Heart Association, Inc.
Figures
Figure 1. Inflammation in plaque rupture and thrombosis
This diagram shows a cross section the intima of part of an artery affected by atherosclerosis. Altered hydrodynamics, illustrated in the upper left, cause loss atheroprotective functions of endothelial cells — including vasodilator, anti-inflammatory, pro-fibrinolytic, and anti-coagulant properties. Antigens presented on antigen-presenting cells such as dendritic cells (DCs) can activate Th1 lymphocytes to produce interferon gamma (IFN-γ), which activates macrophages (MΦ, yellow). Other subtypes of lymphocytes (shown in blue) include Th2 lymphocytes, which can elaborate the anti-inflammatory cytokine interleukin 10 (IL-10) and regulatory T cells that secrete the anti-inflammatory cytokine transforming growth factor beta (TFG-β). On its surface, the macrophage contains Toll-like receptors (TLRs) 2 and 4, which can bind PAMPs and DAMPs (see text). The intracellular TLRs 3, 7, and 9 may also contribute to lipid accumulation and other pro-atherogenic functions of the macrophage. Macrophages can undergo stress of the endoplasmic reticulum (ER) under atherogenic conditions. Cholesterol crystals found in plaques can activate the NLRP3 inflammasome (see text) that can generate mature IL-1β from its inactive precursor. The activated macrophage secretes collagenases that can degrade the triple helical interstitial collagen that lends strength to the plaque's fibrous cap. Activated macrophages also express tissue factor, a potent pro-coagulant, and elaborate pro-inflammatory cytokines that amplify and sustain the inflammatory process in the plaque. When the plaque ruptures due to a collagen-poor, weakened fibrous cap, blood in the lumen can contact tissue factor in the lipid core, triggering thrombus formation (red). When the thrombus forms, polymorphonuclear leukocytes (PMNs) can accumulate and elaborate myeloperoxidase (MPO), which in turn elaborates the potent pro-oxidant hypochlorous acid. Dying PMNs extrude DNA that can form neutrophil extracellular traps (NETs), which can entrap leukocytes and promote thrombosis. Other inflammatory cells modulate atherosclerosis. B2 lymphocytes secrete natural antibody that can inhibit plaque inflammation. On the other hand, B1 lymphocytes, in part via B-cell activating factor (BAFF), can promote inflammation and plaque complication. Mast cells can augment atherogenesis by releasing histamine and the cytokines IFN-γ and IL-6. The consequences of a given plaque rupture depend not only on the solid state of the intimal plaque, but also on the fluid phase of blood, as depicted in the upper right. Systemic inflammation can give rise to cytokines, culminating in the overproduction of IL-6, the trigger of the hepatic acute phase response. The acute phase reactant fibrinogen participates directly in thrombus formation. Another acute phase reactant, plasminogen activator inhibitor-1 (PAI-1), can impair fibrinolysis by inhibiting the endogenous fibrinolytic mediators, urokinase and tissue-type plasminogen activators (uPA and tPA).
Figure 2. Life, death, and transit of macrophages in generating the plaque's “necrotic” core
Blood monocytes interact with adhesion molecules expressed by endothelial cells exposed to inflammatory mediators. They first roll and attach more firmly, and ultimately diapedese into the intima in response to chemoattractant molecules that bind to surface receptors on the leukocyte — exemplified here by chemokine receptor 2 (CCR2). The monocytes recruited to the intimal lesion can proliferate, giving rise to daughter cells, or can differentiate into macrophages with a pro-inflammatory slant (denoted M1) or those that are alternatively activated (denoted M2). Macrophages can traffic, including leaving the plaque by emigration, as shown here on the macrovascular surface. Retention factors such as netrin-1 or semaphorin-3 can promote retention accumulation of mononuclear phagocytes in the plaque. Macrophages can die by oncosis (sometimes called necrosis) or by programmed cell death (apoptosis). Advanced plaques show a defect in clearance of apoptotic cells leading to their accumulation, a process denoted “mummification” due to a defect in efferocytosis (see text). Dying cells can also release apoptotic bodies and microparticles bearing the potent pro-coagulant tissue factor that triggers thrombus formation in disrupted plaques. The detritus of dead and dying cells that accumulate due to defective efferocytosis give rise to the lipid-rich “necrotic” core of the plaque.
Similar articles
- Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes.
Baruch A, van Bruggen N, Kim JB, Lehrer-Graiwer JE. Baruch A, et al. Curr Atheroscler Rep. 2013 Jun;15(6):327. doi: 10.1007/s11883-013-0327-7. Curr Atheroscler Rep. 2013. PMID: 23636864 Review. - The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations.
Cimmino G, Conte S, Morello A, D'Elia S, Marchese V, Golino P. Cimmino G, et al. Expert Rev Cardiovasc Ther. 2012 Dec;10(12):1533-43. doi: 10.1586/erc.12.157. Expert Rev Cardiovasc Ther. 2012. PMID: 23253277 Review. - Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI.
Srikanth S, Ambrose JA. Srikanth S, et al. Curr Cardiol Rev. 2012 Aug;8(3):168-76. doi: 10.2174/157340312803217247. Curr Cardiol Rev. 2012. PMID: 22920487 Free PMC article. Review. - The Role of Different Monocyte Subsets in the Pathogenesis of Atherosclerosis and Acute Coronary Syndromes.
Idzkowska E, Eljaszewicz A, Miklasz P, Musial WJ, Tycinska AM, Moniuszko M. Idzkowska E, et al. Scand J Immunol. 2015 Sep;82(3):163-73. doi: 10.1111/sji.12314. Scand J Immunol. 2015. PMID: 25997925 Review. - Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients.
Canducci F, Saita D, Foglieni C, Piscopiello MR, Chiesa R, Colombo A, Cianflone D, Maseri A, Clementi M, Burioni R. Canducci F, et al. PLoS One. 2012;7(8):e42283. doi: 10.1371/journal.pone.0042283. Epub 2012 Aug 6. PLoS One. 2012. PMID: 22879930 Free PMC article.
Cited by
- Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients.
Cancro FP, Bellino M, Silverio A, Di Maio M, Esposito L, Palumbo R, Manna ML, Formisano C, Ferruzzi G, Vecchione C, Galasso G. Cancro FP, et al. Transl Med UniSa. 2024 Aug 28;26(2):99-110. doi: 10.37825/2239-9747.1058. eCollection 2024. Transl Med UniSa. 2024. PMID: 39385797 Free PMC article. Review. - Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.
Băghină RM, Crișan S, Luca S, Pătru O, Lazăr MA, Văcărescu C, Negru AG, Luca CT, Gaiță D. Băghină RM, et al. J Clin Med. 2024 Aug 27;13(17):5088. doi: 10.3390/jcm13175088. J Clin Med. 2024. PMID: 39274304 Free PMC article. Review. - Clinical Updates in Coronary Artery Disease: A Comprehensive Review.
Bottardi A, Prado GFA, Lunardi M, Fezzi S, Pesarini G, Tavella D, Scarsini R, Ribichini F. Bottardi A, et al. J Clin Med. 2024 Aug 6;13(16):4600. doi: 10.3390/jcm13164600. J Clin Med. 2024. PMID: 39200741 Free PMC article. Review. - Research Landscape on Atherosclerotic Cardiovascular Disease and Inflammation: A Bibliometric and Visualized Study.
Tian W, Zhang T, Wang X, Zhang J, Ju J, Xu H. Tian W, et al. Rev Cardiovasc Med. 2022 Sep 14;23(9):317. doi: 10.31083/j.rcm2309317. eCollection 2022 Sep. Rev Cardiovasc Med. 2022. PMID: 39077721 Free PMC article. - Cardiovascular Disease in Post-Acute COVID-19 Syndrome: A Comprehensive Review of Pathophysiology and Diagnosis Approach.
Kusumawardhani NY, Putra ICS, Kamarullah W, Afrianti R, Pramudyo M, Iqbal M, Prameswari HS, Achmad C, Tiksnadi BB, Akbar MR. Kusumawardhani NY, et al. Rev Cardiovasc Med. 2023 Jan 13;24(1):28. doi: 10.31083/j.rcm2401028. eCollection 2023 Jan. Rev Cardiovasc Med. 2023. PMID: 39076856 Free PMC article. Review.
References
- Libby P. Mechanisms of the acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004–2013. - PubMed
- Falk E, Virmani R. Circulation Research. 2014;114:xxx–xxx. [in this issue] - PubMed
- Falk E, Nakano M, Benton JF, Finn AV, Virmani R. Update on acute coronary syndromes: The pathologists' view. Eur Heart J. 2013;34:719–728. - PubMed
- Yonetsu T, Kakuta T, Lee T, Takahashi K, Kawaguchi N, Yamamoto G, Koura K, Hishikari K, Iesaka Y, Fujiwara H, Isobe M. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J. 2011;32:1251–1259. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 HL117226/HL/NHLBI NIH HHS/United States
- HL119587/HL/NHLBI NIH HHS/United States
- R01 HL107497/HL/NHLBI NIH HHS/United States
- HL098055/HL/NHLBI NIH HHS/United States
- P01 HL054591/HL/NHLBI NIH HHS/United States
- HL080731/HL/NHLBI NIH HHS/United States
- HL080472/HL/NHLBI NIH HHS/United States
- HL054591/HL/NHLBI NIH HHS/United States
- R01 HL080472/HL/NHLBI NIH HHS/United States
- DK095684/DK/NIDDK NIH HHS/United States
- HL075662/HL/NHLBI NIH HHS/United States
- P01 HL087123/HL/NHLBI NIH HHS/United States
- R01 HL084312/HL/NHLBI NIH HHS/United States
- P01 HL098055/HL/NHLBI NIH HHS/United States
- R01 HL075662/HL/NHLBI NIH HHS/United States
- HL084312/HL/NHLBI NIH HHS/United States
- HL106019/HL/NHLBI NIH HHS/United States
- R01 DK095684/DK/NIDDK NIH HHS/United States
- R01 HL106019/HL/NHLBI NIH HHS/United States
- K99 HL119587/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical